Abstract PS5-08-29: Trend-02 study - a phase ii exploratory de-escalation trial of neoadjuvant sacituzumab govitecan plus tislelizumab (sg/i) in early triple-negative breast cancer

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-02-17
DOI
https://doi.org/10.1158/1557-3265.sabcs25-ps5-08-29
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract PS5-08-29: Trend-02 study - a phase ii exploratory de-escalation trial of neoadjuvant sacituzumab govitecan plus tislelizumab (sg/i) in early triple-negative breast cancer

Yuan Wei, Liping Chen, Quanxiu Jin, M. Cui et al.
Clinical Cancer Research
Advanced Breast Cancer Therapies
article

Abstract PS5-08-29: Trend-02 study - a phase ii exploratory de-escalation trial of neoadjuvant sacituzumab govitecan plus tislelizumab (sg/i) in early triple-negative breast cancer

Yuan Wei, Liping Chen, Quanxiu Jin, M. Cui, M. Wang, S. Li, L. Yao, Y. Li, Z. Liao, Y. Xu, Q. Zhang
article en

Abstract

No abstract available for this paper.
Clinical Cancer ResearchVol. 32(4_Supplement)
First Hospital of China Medical University (CN), Liaoning Cancer Hospital & Institute (CN), China Medical University (CN)
Good health and well-being
Openalex Percentile: Top 52%
Advanced Breast Cancer Therapies
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.